[Itching following therapy with hydroxyethyl starch (HES) in otoneurological diseases].
It is generally assumed, that a disturbance of microcirculation is the common pathogenetic end factor in various cochleovestibular disorders of different etiology. Therefore improvement of microcirculation is an important therapeutic goal. Several studies demonstrated, that hydroxyethylstarch (HES) has better haemorheological effects than Dextran and less side effects. For this reason we have changed the therapy with Dextran since 1987 to hydroxyethylstarch in several oto-neurological disorders (as sudden hearing loss, neuronopathia vestibularis, idiopathic facial palsy). As after the therapy with HES--generally after dismissal from the ENT-department--some patients complained of general pruritus, so we performed a retrospective study with a standardized interview-protocol. Of 481 treated patients we investigated 237 (49%): of 149 patients treated with HES 200/0.5, 43 patients (28.8%) complained of pruritus; from 88 patients treated with Dextran 40, only 5 patients (5.7%) reported pruritus. The difference is significant (p less than 0.0001). In nearly half of the patients (more than 40%) the pruritus started in normal skin 1 to 3 weeks after the HES-therapy and lasted for 6 weeks to 6 months; the itching was very resistant to therapy (f.e. with antihistaminics). We want to draw the attention to this possible, in the literature until now quite neglected, for some patients extremely uncomfortable and socially embarrassing side effects after HES-therapy when given in relatively high doses. It is therefore suggested therapeutic recommendations should be developed to prevent this undesired side effect.
Hals-Nasen-Ohrenabteilung, St. Johann's Spitals, Salzburg.
K
K
Albegger
R
R
Schneeberger
V
V
Franke
G
G
Oberascher
K
K
Miller
D015834:Cochlear Diseases / Q000188:drug therapy* / Q000503:physiopathology; D003911:Dextrans / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005158:Facial Paralysis / Q000188:drug therapy; D005260:Female; D006319:Hearing Loss, Sensorineural / Q000188:drug therapy; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008833:Microcirculation / Q000187:drug effects*; D008875:Middle Aged; D011537:Pruritus / Q000139:chemically induced*; D012189:Retrospective Studies; D014012:Tinnitus / Q000188:drug therapy; D014717:Vertigo / Q000188:drug therapy
D003911:Dextrans; D006895:Hydroxyethyl Starch Derivatives
Juckreiz nach Therapie mit Hydroxyäthylstärke (HES) bei otoneurologischen Erkrankungen.